PRP in pain therapy: beyond the joints - new indications and protocols

  • News
  • likes
  • 43427 views
  • PRP pain therapy, Neuropathic pain, Fascia pain, Chronic back pain
PRP knowledge · Evidence status September 2026

PRP in pain management: evidence by diagnosis, not blanket promises

PRP is being studied for very different pain conditions. The decisive issue is not the symptom “pain” but its cause: joint osteoarthritis, tendinopathy, spinal pain and neuropathic pain have different biology, comparators and evidence.

The key point

PRP is not a conventional analgesic and not a uniform pain treatment. Current evidence is indication-specific: knee osteoarthritis has the broadest evidence base, while placebo-controlled analyses in lateral epicondylitis and Achilles tendinopathy show no convincing benefit. Evidence for spinal and neuropathic applications is growing but remains heterogeneous.

Principle

Why PRP might influence pain – without being a painkiller

Clinical pain reduction may result from several local processes. Mechanistic plausibility, however, is not proof of efficacy – the bars indicate how closely the clinical evidence currently supports each hypothesis.

clinically indication-dependent

Inflammatory and immune milieu

Platelets release mediators that may influence local inflammatory and resolution pathways. Direction and magnitude depend on tissue and PRP composition.

predominantly preclinical

Tissue response and matrix

PRP is investigated for effects on cell signalling, matrix remodelling and repair. Less pain does not prove structural regeneration.

early research field

Neuroimmune pathways

In neuropathic and chronic pain, effects on neuroimmune communication and peripheral nerves are being studied. Clinical evidence is much narrower than the biological hypothesis.

The bars are a schematic editorial indication of how close each hypothesis is to clinical evidence; they are not a validated evidence score or a GRADE assessment.

Time course

What a large pain meta-analysis shows about timing

A 2025 meta-analysis of 56 RCTs involving 7,142 patients pooled different chronic non-cancer pain conditions. These pooled values are not treatment instructions, but they show why follow-up timing matters.

SMD = standardized mean difference. In this analysis, a negative value indicates lower pain scores with PRP. The bands show the usual reference ranges for effect sizes (small/moderate/large); confidence intervals are not shown here. Source 01 ↓

And for individual indications? When each analysis found a difference

The time-window matrix focuses primarily on pain outcomes and shows at which follow-up points the cited meta-analyses reported a significant difference. Functional scores may differ. Filter by comparator and select a cell for the exact finding.

Compared with:
Analysis≈ 1 month≈ 3 months≈ 6 months12 months
Chronic pain, pooled56 RCTs · active controls/placebo · Source 01
Plantar fasciopathy24 RCTs · vs corticosteroid · Source 07
Rotator cuff10 RCTs · vs corticosteroid · Source 10 not reported
Lateral epicondylitis6 RCTs · vs placebo · Source 08 not reported
Achilles tendinopathyRCT meta-analysis · vs placebo · Source 09

How to read: The same “6-month benefit” means something different versus corticosteroid than versus placebo. Week-based follow-ups were assigned to the nearest column.

Indications

Evidence explorer: the same acronym, very different results

Select a diagnosis on the body diagram or in the tab bar. The assessment is based preferentially on current RCT meta-analyses and guidelines; it is not a treatment recommendation.

Broad evidence basemixedvs placebo · MA 2025
Largest evidence base among the indications considered here

Evidence is most extensive here. The German S3 guideline allows PRP to be considered in symptomatic knee OA when other pain- and function-improving measures are unsuitable, contraindicated or ineffective. A 2025 placebo-controlled meta-analysis, however, found only weak or time-dependent effects with high heterogeneity.

Differences in PRP products, OA grade, comparator and follow-up prevent a simple statement that “PRP works for knee OA”.

Source 02 ↓ · Guideline comparison ↓

Compared with corticosteroidtime-dependent signalvs corticosteroid
24 RCTs · 1,653 patients

A 2025 meta-analysis of 24 RCTs and 1,653 patients found better pain scores than corticosteroid at 3 and 6 months, but no significant difference at 1 or 12 months.

Superiority to corticosteroid does not automatically mean superiority to placebo; comparator and study design change the conclusion.

Source 07 ↓

PRP vs corticosteroidmodest 6-month benefitvs corticosteroid
10 RCTs · 591 patients

A 2026 meta-analysis of 10 RCTs and 591 patients found no clear difference short term or at 3 months. At 6 months, ASES, Constant-Murley and pain outcomes favoured PRP.

Results concern tendinopathy or partial tears and cannot be transferred to every cause of shoulder pain.

Source 10 ↓

Placebo controlledno convincing benefitvs placebo
6 RCTs · 355 patients

A 2026 meta-analysis of six RCTs and 355 patients found no significant advantage in pain or function at 4, 8–12 or 24–26 weeks versus placebo.

Comparisons with corticosteroid or whole blood may differ. Placebo is particularly relevant when asking about a specific PRP effect.

Source 08 ↓

Placebo controlledno proven benefitvs placebo
meta-analysis of randomized trials 2026

A 2026 meta-analysis of randomised trials found no significant benefit over placebo for VISA-A, pain or sonographic outcomes.

This argues against blanket efficacy claims for Achilles tendinopathy; rehabilitation and a precise diagnosis remain central.

Source 09 ↓

15 RCTs in low back painpromising, heterogeneousmixed controls
15 RCTs · 740 patients

A 2026 meta-analysis of 15 RCTs and 740 patients found pooled improvements in pain and disability. Later effects in discogenic pain were inconsistent and heterogeneity was substantial. A double-blind facet-joint RCT, however, found no superiority.

“Low back pain” includes disc, facet, sacroiliac joint, nerve root and other structures. Pooled data cannot be transferred to every target.

Source 11 ↓ · 12 ↓ · 13 ↓

12 randomised studiesearly research fieldheterogeneous designs
12 randomised studies · no pooled meta-analysis feasible

A 2025 systematic review identified 12 randomised trials. Heterogeneity was too high for a meaningful pooled meta-analysis. Many individual studies reported signals favouring PRP, but no robust cross-condition conclusion follows.

Neuropathic pain is not a single disease. Carpal tunnel, traumatic nerve lesions and other causes must be assessed separately.

Source 14 ↓ · 15 ↓

Time-dependent benefit vs corticosteroidInconsistent / heterogeneousNo benefit vs placeboEarly research fieldBar: number of RCTs relative to the largest analysis cited here
Guidelines

Knee osteoarthritis: why guidance can judge the same evidence differently

This is not necessarily contradiction: methods, health systems and recommendation thresholds differ.

2025 · Recommendation 27
  1. FirstOther analgesic and function-improving measures
  2. If these …are unsuitable, contraindicated or ineffective
  3. ThenPRP may be considered

PRP may be considered for symptomatic knee OA when other analgesic and function-improving measures are unsuitable, contraindicated or ineffective. The guideline emphasises heterogeneous study quality and does not recommend a specific preparation method.

This is an option to consider, not a blanket recommendation for every patient. · Source 03 ↓

2024 · RAND/UCLA
Simplified summary of the RAND/UCLA consensus. The original paper evaluates 216 individual scenarios by age, osteoarthritis grade, compartment, effusion and treatment stage; this table is therefore not an individual decision rule.
ScenarioConsensus assessment
PRP as first treatmentmostly uncertain or inappropriate
After failed conservative or injectable treatment, KL 0–IIImore often rated appropriate
KL IVmostly uncertain; not generally rated appropriate

Of 216 scenarios, 38.9% were rated appropriate, 4.2% inappropriate and 56.9% uncertain. Agreement was highest for PRP after failed prior treatments; uncertainty was particularly high for PRP as first treatment and for KL IV. The assessment therefore depends on the specific clinical scenario.

Patient selection and treatment stage are part of the judgement. · Source 04 ↓

HTG497 / IPG637
Safety
major concernspartlyno major concerns
Efficacy evidence
limited qualitymoderaterobust
Safeguards
GovernanceConsentAudit / research

NICE reports no major safety concerns but considers efficacy evidence limited in quality and calls for special arrangements for governance, consent and audit or research.

A useful example of why safety and proof of efficacy are separate questions. · Source 06 ↓

PRP quality

Why “PRP” may not mean the same biological product in two studies

International consensus and reporting work therefore calls for precise characterization. Configure two study protocols – both might simply be reported as “PRP” in a publication.

1of 6 parameters match

Even this highly simplified grid yields 384 different protocols.

PLTPlatelets

Baseline value, final concentration, total count and administered dose can differ substantially.

different
WBCLeukocytes

Leukocyte-rich and leukocyte-poor PRP are biologically different. Even the neutrophil fraction may matter.

different
RBCRed cells

Residual erythrocytes should be reported. Different separation systems produce different cellular profiles.

different
ACTActivation

Calcium, thrombin, mechanical/endogenous activation or no ex-vivo activation are not equivalent protocols.

different
DOSEDose / volume

Total platelet count, injection volume and number of applications may be relevant; a universal optimal dose has not been established.

same
TARGETTarget / technique

Intra-articular, intratendinous, perineural and epidural applications differ biologically and in their safety considerations.

different

Simplified teaching grid without cut-offs; for full classification using established systems, use the classification tool.

Open the PRP classification tool →

QuestionSupported conclusionDo not infer
Pain reductionFor selected diagnoses and time points, RCTs or meta-analyses show differences favouring PRP.That PRP works for chronic pain in general.
RegenerationBiological repair and matrix processes are being investigated.That less pain proves newly formed healthy tissue.
Compared with steroidIn some tendinopathies the relative advantage changes over time.That PRP is therefore automatically better than placebo or standard care.
PreparationCell composition, activation, dose and delivery should be reported.That a study protocol can be transferred to every tube or centrifuge.
Long-term benefitSome analyses show stronger effects after several months.That a delayed effect should be expected for every indication or patient.
Practice

For professionals: eight quality questions before interpreting a PRP pain study

Tick the questions the study in front of you answers. What remains unclear limits transferability.

0 of 8 questions answered

Read more on PRPMED

The PRP classification tool helps distinguish technical PRP characteristics. A separate professional article covers contraindications and patient selection.

PRP classification tool →

PRP: side effects and risks →

FAQ

Is PRP a painkiller?

No. PRP is investigated as an autologous biological procedure. Any pain reduction would reflect local biological changes, not the direct pharmacology of an analgesic.

Which pain condition has the strongest PRP evidence base?

Among the indications discussed here, knee osteoarthritis is the most extensively studied. Results and guideline assessments are still not uniform.

Does PRP help tennis elbow?

A recent placebo-controlled meta-analysis of six RCTs found no significant benefit for pain or function. Other comparator groups may yield different results.

What about Achilles tendinopathy?

Current placebo-controlled meta-analyses show no convincing clinical benefit. Blanket efficacy claims are therefore not justified.

Why are there positive and negative statements for plantar fasciitis?

One reason is the comparator. Some meta-analyses show medium-term advantages versus corticosteroid, while stricter placebo or blinded analyses can be much more cautious.

Is PRP proven for low back pain?

Randomised evidence is growing, but low back pain covers different target structures. Pooled results are heterogeneous and individual high-quality trials may be neutral.

Are there data for neuropathic pain?

Yes, but the field remains heterogeneous. A 2025 review found 12 randomised studies but could not perform a pooled meta-analysis because of their differences.

Can a positive study protocol be transferred to every PRP system?

No. Composition, dose, activation, preparation and delivery can differ substantially. Manufacturer instructions and intended purpose of the system remain decisive.

References

References

Platelet-Rich Plasma for Treating Chronic Noncancer Pain: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

  1. PubMed / Full text Wang et al. 2025. PubMed
  2. PubMed / Full text Auroux et al. 2025. PubMed
  3. PubMed / Full text AWMF S3 Gonarthrose 2025. AWMF register (PDF)
  4. PubMed / Full text Kon et al. 2024. PubMed
  5. PubMed / Full text ESSKA-ORBIT 2024. PubMed
  6. PubMed / Full text NICE HTG497. NICE
  7. PubMed / Full text Zuo et al. 2025. PubMed
  8. PubMed / Full text Antunes Júnior et al. 2026. PubMed
  9. PubMed / Full text Assi et al. 2026. PubMed
  10. Yuwarungsikul et al. 2026. Rotator cuff meta-analysis 2026. PubMed
  11. PubMed / Full text Pei et al. 2026. PubMed
  12. Alatefi et al. 2026. Facet/SIJ meta-analysis 2026. PubMed
  13. Geoffroy et al. 2026 (Epub 2025). Facet RCT 2025/2026. PubMed
  14. PubMed / Full text de Jesus et al. 2025. PubMed
  15. Du et al. 2025. Carpal tunnel meta-analysis 2025. PubMed
  16. Hurley et al. 2024 (Epub 2023). Experts Achieve Consensus on a Majority of Statements Regarding Platelet-Rich Plasma Treatments for Treatment of Musculoskeletal Pathology. PubMed
  17. PubMed / Full text MIBO 2017. PubMed
  18. PubMed / Full text Kuffler 2013. PubMed
  19. Buchheit et al. 2020. Neuroimmune pain review 2020. PubMed
  20. PubMed / Full text Roffi et al. 2014. PubMed

Professional information for medical practitioners. This article contextualizes published evidence and is not an individual diagnostic, preparation or treatment instruction. Several applications are not standardized by indication, product or country and may be off-label. The graphics are simplified representations of the cited publications. Clinical judgment, current guidelines, manufacturer information, intended purpose and applicable law remain decisive.

Related products

Vi PRP-PRO | Buy PRP Tubes - Safe & Efficient Vi PRP-PRO | Buy PRP Tubes - Safe & Efficient 2
immediately available
PRP

PRP tubes | Vi PRP-PRO | with Anticoagulant PU 10 pieces

PRPMED Professional Cosmetic Treatments
100101
€131.00
The VI PRP-PRO glass tube offers a modern solution for producing platelet-rich plasma (PRP) and ensures additional stability and reliability in treatments with a wall thickness of 2.4 mm. Developed with innovative technology and EC-certified (0425-MED-004180-00), it guarantees the highest level of safety and efficiency. Key Features: Certified...
Product added to wishlist
Product added to compare.
group_work Cookie consent